ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) Clinical Trial
Official title:
A Research Study to Describe the Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS). An Assessment of Two Case Studies
This protocol is intended to formally collect data on the treatment of aHUS with eculizumab in Japanese patients.
Status | Completed |
Enrollment | 2 |
Est. completion date | July 2012 |
Est. primary completion date | May 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: 1. Patient and/or legal guardian must be willing and able to give written informed consent and id the patient is not an adult and able to read and write, the patient is willing to give written informed assent 2. Eculizumab treatment initiated as personal importation for aHUS in 201 Exclusion Criteria: |
Time Perspective: Retrospective
Country | Name | City | State |
---|---|---|---|
Japan | Shinshu University School of Medicine | Matsumoto | |
Japan | Tokyo Medical and Dental University | Tokyo |
Lead Sponsor | Collaborator |
---|---|
Alexion Pharmaceuticals |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in platelet count from baseline | 26 weeks | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01757431 -
The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
|
Phase 2 | |
Not yet recruiting |
NCT06312644 -
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
|
||
Completed |
NCT02949128 -
Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
|
Phase 3 | |
Completed |
NCT03131219 -
Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)
|
Phase 3 | |
Completed |
NCT01770951 -
A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
|